Objective  To analyze the therapeutic efficacy and adverse reaction induced by Jin Long Capsule (JLC) combined with TEC regimen (docetaxel+epirubicin+cyclophosphamide) in neoadjuvant chemotherapy of breast cancer.

  Methods  A total of 64 patients who had stages Ⅱ to Ⅲ breast cancer were divided into two groups randomly:JLC combined with neoadjuvant chemotherapy group (JLC group, n=32) and conventional neoadjuvant chemotherapy group (control group, n=32). The chemotherapy cycle was 21 d equally. Evaluations of therapeutic effects were made after three cycles of neoadjuvant chemotherapy and consequent operation.

  Results  The effective powers (complete response+ partial response) of the JLC group and the control group were 84.38% (27/32 cases) and 56.25% (18/32 cases), respectively. The difference was statistically significant (P < 0.05). The main adverse effects were grades Ⅱ to Ⅲ gastrointestinal tract indisposition and myelosuppression. WBC decrease and incidence rate of nausea and vomiting were obviously lower in the JLC group than in the control group (P < 0.05). The life quality of patients in the JLC group was greatly improved than that in the control group (P < 0.05).

  Conclusion  The application of JLC combined with neoadjuvant chemotherapy can improve therapeutic efficacy and reduce the poisonous side effects of chemotherapy, thereby improving the life quality of patients.